Thrombolytic, antiplatelet, and antithrombotic agents
- 21 December 1992
- journal article
- review article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 70 (21) , I18-I26
- https://doi.org/10.1016/0002-9149(92)90261-v
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Prospects for the use of antagonists to the platelet glycoprotein IIb/ IIIa receptor to prevent postangioplasty restenosis and thrombosisJournal of the American College of Cardiology, 1991
- Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinaseJournal of the American College of Cardiology, 1988
- A Randomized Trial of Immediate versus Delayed Elective Angioplasty after Intravenous Tissue Plasminogen Activator in Acute Myocardial InfarctionNew England Journal of Medicine, 1987
- Appraisal of various thrombolytic agents in the treatment of acute myocardial infarctionThe American Journal of Medicine, 1987
- A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (activase) in acute myocardial infarctionJournal of the American College of Cardiology, 1987
- Competitions between fibrinogen with its degradation products for interactions with the platelet-fibrinogen receptorThrombosis Research, 1986
- The Thrombolysis in Myocardial Infarction (TIMI) TrialNew England Journal of Medicine, 1985
- RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1985
- Hemodynamic Reactions Induced by Streptokinase Therapy in Patients with Acute Myocardial InfarctionIntensive Care Medicine, 1975
- Effect of fibrinogen degradation products on platelet aggregationJournal of Clinical Pathology, 1968